In vivo, platelets associate with neutrophils at sites of hemorrhage or inflammation. In vitro, stimulated platelets bind to neutrophils in a Ca2+-dependent manner. GMP-140, an integral membrane glycoprotein found in secretory granules of platelets and endothelium, is rapidly translocated to the cell surface after cellular activation. It shares sequence similarity with two leukocyte adhesion molecules, ELAM-I and a lymphocyte homing receptor. We have recently shown that neutrophils bind to purified GMP-140 in a Ca2+-dependent fashion, and that GMP-140 participates in adhesion of neutrophils to activated endo-
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thelium. In this study we demonstrate that GMP-140 also mediates adhesion of neutrophils to stimulated platelets. Fixed thrombin-activated human platelets, but not unstimulated platelets, formed rosettes around neutrophils in the presence of Ca2+. The binding of platelets to neutrophils was inhibited by a monoclonal antibody to GMP-140 and by purified GMP-140. By as PADGEM protein or CD62,17 is an integral membrane glycoprotein found in secretory granules of both platelets's-2' and endothelial ~e l l s .~~-'~ After activation of these cells by agonists such as thrombin, it is rapidly redistributed to the cell surface during degranulation. GMP-14025 belongs to the selectin family of vascular cell surface receptors that share sequence similarity and overall domain organization. 26 The other known selectins are ELAM-1, a cytokine-inducible endothelial cell receptor for neutrophil^,^^ and a leukocyte surface structure best studied for its role in directing the homing of lymphocytes to high endothelial venules of peripheral lymph node^.^'^^^ The fact that these two molecules both direct adhesion of leukocytes to other vascular cells suggested that GMP-140 might have a similar function. We have recently shown that human neutrophils bind in a Ca2+-dependent manner to purified GMP-140 immobilized on plastic.30 Furthermore, adhesion of neutrophils to endothelium stimulated with rapid activators such as histamine is mediated a t least in part by GMP-140.3' In this study we demonstrate that GMP-140 is also involved in binding of activated platelets to neutrophils.
MATERIALS AND METHODS
Hanks balanced salt solution (HBSS) without added divalent cations and HBSS containing 1.26 mmol/L CaZ+ and 0.81 mmol/L Mg2+ (HBSS/Ca) were obtained from Flow Laboratories Inc, Maclean, VA. Divalent cations in HBSS were further depleted by passing buffer through a 2.5 x 30 cm column (Pharmacia LKB Biotechnology Inc, Piscataway, NJ) containing Chelex-1 00 resin (Bio-rad Laboratories, Richmond, CA). The Ca2+ concentration of Chelex-treated HBSS (HBSS/CLX) was 15.5 pmol/L as determined by atomic absorption spectrophotometry (Varian Techtron, Model 1200, Sugarland, TX).
All antibodies were used as purified immunoglobulin G (IgG) dissolved in phosphate buffered saline (PBS), pH 7.4. The monoclonal antibodies (MoAbs) S1218,32 and Gl,9°,3' are both specific for GMP-140. Both antibodies bind to the nonreduced form of GMP-140 on immunoblots, but only G1 inhibits adhesion of neutrophils to purified immobilized GMP-1403' or to activated endotheli~m.~' T10 identifies a Caz+-dependent epitope on the platelet glycoprotein IIb-IIIa c o m p l e~.~) "~ S12, G1, and T10 are all IgG, antibodies.
GMP-140, purified from human platelet lysates by immunoaffinity chromatography on S12-Sepharose" and ionexchange chromatography on a Mono-Q column (FPLC, Pharmacia LKB Biotechnology, Piscataway, NJ), was dissolved in 20 mmol/L Tris-HC1, pH 7.5 (TBS), containing 0.01% Lubrol PX at a concen-
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tration of 0.78 mg/mL. Rabbit thrombomodulin. a gift from Dr Naomi Esmon (Oklahoma Medical Research Foundation, Oklahoma City), was isolated at described" and dissolved in TBS containing 0.02% Lubrol PX at a concentration of 1 mg/mL. Purified human platelet glycoprotein IIb-llIa,'6 a gift from Dr Leslie Parise (University of North Carolina, Chapel Hill), was dissolved in TBScontainingO.l%TritonX-I00at 1.67 mg/mL.
Platelet-rich plasma" isolated from normal human blood was centrifuged at 300 IO" cells/mL, was exposed to bovine thrombin" (0.1 U/mL final concentration) or diluent for IO minutes at 37OC. The platelets were then fixed with 1 mL of 8% paraformaldehyde for 60 minutes a t room temperature. Fixation was stopped by the addition of 1 mL of a solution containing 250 mmol/L Tris and 500 mmol/L glycine. After 15 minutes at room temperature. the platelets were washed three. times with HBSS/CLX.
Blood from the platelet donor was also collected into bovine lung heparin (Upjohn Co., Kalamazoo, MI) at a final concentration of IO U/mL. Neutrophils were isolated using Mono-poly Resolving Media (Flow Laboratories, Maclean, VA), which is composed of Ficoll-400 and Hypaque 85 in a ratio that yields a density of 1.1 14. This method rapidly resolves neutrophils from other blood components without the need for hypotonic lysis of red blood cells. Cells were washed and resuspended to a concentration of 0.9 to 1.4 x lO'cells/mL in either HBSS/CLX or HBSS/Ca. Neutrophil suspensions were greater than 98% pure and greater than 95% viable as assessed by trypan blue exclusion. Rosette assay. The binding of platelets to neutrophils was examined using minor modifications of the method of Jungi et al."
Thirty-microliter aliquots of fixed platelets (1.5 to 2.0 x IO* cells/mL in HBSS/CLX) were placed in sterile microtiter wells. Then 10 pL of either HBSS/CLX. HBSS/Ca, or MoAb was added and incubated for 15 minutes at room temperature. Then 30 pL of neutrophils, yielding a final concentration of 4.5 to 6.0 x IO6 platelets/mL and 2.6 to 4.2 x IO' neutrophils/mL (platelet/ neutrophil ratio of 18 to 27:l) was added to the platelet suspension.
The final concentration of each MoAb was IO pg/mL. In some experiments EDTA or EGTA (final concentration of 1 mmol/L) was added. In other experiments, buffers containing 1 mg/mL of bovine serum albumin were used. To determine whether GMP-140 could inhibit binding of platelets to neutrophils, IO pL of either purified GMP-140, the control membrane proteins glycoprotein Ilb-Illa or thrombomodulin. or buffer containing an equivalent amount of nonionic detergent were preincubated with 30 pL of neutrophils for 30 minutes at room temperature before addition of 30 pL of platelets. The final concentration of purified protein in each case was 35 pg/mL and the final concentration of Ca" was 1.6 mmol/L. After 30 minutes. 17 r L of the contents of each platelet-neutrophil suspension were placed on a microscope slide over which a glass coverslip was positioned. The cell suspension was examined under water immersion with a Zeiss Photomicroscope 2 (Thornwood. NJ). One hundred neutrophils were scored for the presence (two or more platelets per neutrophil) or absence (zero or one platelet per neutrophil) of platelets. Thus, neutrophils bearing two or more platelets were defined as rosettes.
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RESULTS
As previously noted," relatively few unstimulated platelets bound to neutrophils. Only 15% of neutrophils rosetted two or more unstimulated fixed platelets (Fig 1) . In contrast, over 60% of neutrophils bound two or more platelets stimulated with thrombin. Furthermore, more stimulated platelets bound to each neutrophil than did unstimulated platelets. The adherence of stimulated platelets to neutrophils was dependent on added Ca", confirming previous result^.'^ In the absence of Ca", the number of neutrophils bearing stimulated platelets was reduced to the levels seen for unstimulated platelets. Addition of 1 mmol/L EGTA or EDTA did not further reduce the number of plateletneutrophil rosettes, although the average number of platelets on each neutrophil was diminished (not shown).
To test the involvement of GMP-140 in platelet-neutrophil interactions, we added neutrophils in Caz'-containing buffers to stimulated platelets in the presence of MoAbs to GMP-140 or control MoAbs. Two different MoAbs to GMP-140 were used: G1, which blocks adhesion of neutrophils to purified GMP-1403' or to activated endothelium," and S12, which does not inhibit adhesion of neutrophils in either of these systems. As shown in Fig 1, G1 , but not S12, inhibited the interaction of neutrophils with stimulated platelets. T10,)3-34 an MoAb to the platelet membrane glycoprotein IIb-IIIa complex that blocks platelet aggregation, did not prevent the association of stimulated platelets with neutrophils. Similar results were seen when higher concentrations of antibodies were used and when human serum albumin (1 mg/mL) was added to all buffers (not shown).
To further test the role of GMP-140 in mediating interaction of stimulated platelets with neutrophils, we preincubated neutrophils with purified fluid-phase GMP-140 or with two control membrane proteins, platelet glycoprotein IlbllIa or thrombomodulin. Figure 2 demonstrates that purified GMP-140, but not the control proteins, inhibited binding of stimulated platelets to neutrophils.
DISCUSSION
We have previously shown that neutrophils bind specifically to purified GMP-140,30 which indicates that GMP-140 is sufficient to support neutrophil adhesion. GMP-140 is a mediator of neutrophil adhesion to the surface of activated endothelium." In this study we demonstrate that it also promotes adherence of neutrophils to the surface of activated platelets. The Ca" dependence of the platelet-neutrophil interaction, previously documented by Jungi et al, l4 resembles the Ca2+ requirement for neutrophil adhesion to purified GMP-140." It is noteworthy that the N-terminal domain of GMP-140~51ikethoseofELAM-127and the Me1 14antibody-defined lymphocyte homing is homologous to a family of Ca2+-dependent lectins." While formal proof is not yet available, it seems possible that this domain is responsible for at least part of the Ca2+-dependent interaction of neutrophils with GMP-140.
The ability of fixed platelets to adhere to neutrophils in a GMP-140-dependent manner indicates that platelets, once they are activated, do not require additional metabolic activity for binding. Nectrophils need not be metabolically active either, because (1) activated platelets interact with neutrophils at 4OC or in the presence of sodium azide,I4 and (2) fixed neutrophils bind to purified GMP-140.30 In addition, neutrophils do not require prior activation to adhere to purified GMP-1403' or to GMP-140 on activated endothelium" or platelets (this study). This suggests that the CDI 1/CD18 leukocyte integrins are not ligands for GMP-140 because one of these integrins. Mac-1 (CDI 1b/CD18), mediates adhesion of activated, but not unactivated, neutrophils to endothelium or matrix.40 Moreover, the antLCD18 MoAb IB434 does not block adhesion of unstimulated neutrophils to activated endothelium" or purified GMP-140." Although metabolic activity is not required for binding of activated platelets to neutrophils, in vivo, platelet-neutrophil contact may have important functional consequences for both cell types. Several studies indicate that products released from activated platelets can promote neutrophil activation, adherence, aggregation, and phagocytosi~?'.~' Other products may inhibit certain neutrophil functions such as superoxide p r o d u~t i o n .~~.~~.~~ Transcellular metabolism of lipid intermediates from one cell type by the other has also been documented."" It is not known whether direct contact between platelets and neutrophils facilitates the modulating role of these soluble products. The ability to block binding of activated platelets to neutrophils with antibodies to GMP-140 may allow this issue to be addressed.
Monocytes also bind to both plateletsI4 and endothelium: suggesting that GMP-140 could promote monocyte adhesion to these cells. In preliminary studies, we found that human monocytoid U937 cells bind to stimulated platelets in a Ca2+-dependent manner and that this adhesive interaction is inhibited by MoAbs to GMP-140. While this paper was under review, Larsen et aI4' reported that GMP-140 mediates binding of stimulated platelets to both neutrophils and monocytes. The relative roles of GMP-140 and other adhesive proteins such as thrombo~pondin''-'~ in plateletleukocyte interactions remain to be determined. By promoting rapid binding of leukocytes to both activated platelets and endothelium, GMP-140 may facilitate communication between the hemostatic and inflammatory responses to tissue injury.
